Global HIV epidemiology: A guide for strategies in prevention and care

Current HIV/AIDS Reports

Volumn 11, Issue 2, 2014, Pages 93-98

  Vermund, Sten H ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Barriers; Epidemiology; Global; Global epidemic; HIV; HIV prevention strategies; Human rights; Men who have sex with men (MSM); Persons who inject drugs (PWID); Prevention; Surveillance

Indexed keywords

BEHAVIOR CHANGE; CONDOM USE; DISEASE TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN RIGHTS; INCIDENCE; MEN WHO HAVE SEX WITH MEN; NEEDLE; NOTE; OPIATE SUBSTITUTION TREATMENT; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; RISK REDUCTION; SYRINGE; UNITED STATES; DISEASE OUTBREAKS; FEMALE; HEALTH; HIV INFECTIONS; MALE; NURSING; PREVALENCE; SENTINEL SURVEILLANCE; TRENDS;

DISEASE OUTBREAKS; FEMALE; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PREVALENCE; SENTINEL SURVEILLANCE;

EID: 84903597679     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0208-x     Document Type: Note

References (92)

1. •• Delva W, Abdool Karim Q. The HIV epidemic in Southern Africa-Is an AIDS-free generation possible? Curr HIV AIDS Rep. 2014; doi:10.1007/s11904-014-0205-0. The authors present an epidemiologic update and prospects for progress in the world's HIV epicenter of southern Africa.
2. Leclerc PM, Matthews AP, Garenne ML. Fitting the HIV epidemic in Zambia: a two-sex micro-simulation model. PLoS One. 2009;4: e5439.
3. Okal J, Geibel S, Muraguri N, et al. Estimates of the size of key populations at risk for HIV infection: men who have sex with men, female sex workers and injecting drug users in Nairobi,Kenya. Sex Transm Infect. 2013;89:366-71.
4. Beyrer C, AbdoolKQ. The changing epidemiology of HIVin 2013. Curr Opin HIV AIDS. 2013;8:306-10.
5. Epstein H, Morris M. Concurrent partnerships and HIV: an inconvenient truth. J Int AIDS Soc. 2011;14:13.
6. Sawers L. Measuring and modelling concurrency. J Int AIDS Soc. 2013;16:17431.
7. •• Suguimoto SP, Techasrivichien T, Musumari PM, et al. Changing patterns of HIV epidemic in 30 years in East Asia. Curr HIV AIDS Rep. 2014; doi:10.1007/s11904-014-0201-4. The authors present both recent trends and challenges of HIVamidst the vast population of East Asia.
8. • Ye S, Pang L, Wang X. Epidemiological implications of HIV hepatitis C co-infection in South and Southeast Asia. Curr HIV AIDS Rep. 2014; doi:10.1007/s11904-014-0206-z. A brief review of HIV-HCV co-infection focused on south and southeast Asia indicates the challenge facing Asia.
9. Samo RN, Altaf A, Agha A, et al. High HIV incidence among persons who inject drugs in Pakistan: greater risk with needle sharing and injecting frequently among the homeless. PLoS One. 2013;8:e81715.
10. Steen R, Zhao P,Wi TE, Punchihewa N, Abeyewickreme I, Lo YR. Halting and reversing HIVepidemics in Asia by interrupting transmission in sex work: experience and outcomes from ten countries. Expert Rev Anti Infect Ther. 2013;11:999-1015.
11. van Griensven F, Thienkrua W, McNicholl J, et al. Evidence of an explosive epidemic of HIV infection in a cohort of men who have sex with men in Thailand. AIDS. 2013;27:825-32.
12. •• Garcia PJ, Bayer A, Cárcamo CP. The changing face of HIV in Latin America and the Caribbean. Curr HIV AIDS Rep. 2014; [In press]. doi:10.1007/s11904-014-0204-1. The authors present a comprehensive assessment of the multifaceted epidemic in the Americas south of the USA/Canada.
13. •• Figueroa JP. Review of HIV in the Caribbean: significant progress and outstanding challenges. Curr HIV AIDS Rep. 2014; doi:10.1007/s11904-014-0199-7. The author describes the complex epidemiology of different island HIV transmission patterns.
14. •• Nakagawa F, Phillips AN, Lundgren JD. HIV in Western Europe. Curr HIV AIDS Rep. 2014; [In press]. doi:10.1007/s11904- 014-0198-8. The authors present a current and historic perspective on Western Europe 's struggle with HIV/AIDS.
15. Vermund SH, Leigh-Brown AJ. The HIV epidemic: high-income countries. Cold Spring Harb Perspect Med. 2012;2:a007195.
16. Plummer D, Irwin L. Grassroots activities, national initiatives and HIV prevention: clues to explain Australia's dramatic early success in controlling the HIVepidemic. Int J STD AIDS. 2006;17:787-93. (Pubitemid 46057732)
17. •• DeHovitz J, Uusküla A, El-Bassel N. The HIV epidemic in Eastern Europe and Central Asia. Curr HIV AIDS Rep. 2014; doi:10.1007/s11904- 014-0202-3. The authors review epidemiologic trends and prevention challenges for the epidemic in Eastern Europe and Central Asia, largely driven by injection drug use.
18. Vagenas P, Azbel L, Polonsky M, et al. A review of medical and substance use co-morbidities in Central Asian prisons: implications for HIV prevention and treatment.DrugAlcohol Depend. 2013;132 Suppl 1:S25-31.
19. • Dunlap J, Foderingham N, Bussell S, Wester CW, Audet CM,Aliyu MH. Male involvement for the prevention of mother-to-child HIV transmission: a brief review of initiatives in East, West and Central Africa. Curr HIV AIDS Rep. 2014; doi:10.1007/s11904-014-0200-5. Concentrating on sub-Saharan Africa exclusive of the 10 nations in southern Africa, the authors highlight an innovative approach to improving PMTCT coverage, namely the engagement of men in antenatal, intrapartum, and postpartum care.
20. • Roxby AC, Unger JA, Slyker JA et al. A lifecycle approach to HIV prevention in African women and children. Curr HIV AIDS Rep. 2014; doi:10.1007/s11904-014-0203-2. The authors put HIV care in the broader context of overall health and prevention needs, describing a lifecycle approach for sustained epidemic response.
21. Crosby RA. State of condom use in HIV prevention science and practice. Curr HIV AIDS Rep. 2013;10:59-64.
22. Baeten JM, Haberer JE, Liu AY, Sista N. Pre-exposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S122-9.
23. Amico KR,Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143-55.
24. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369:1828-35.
25. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012;366:2368-79.
26. Tieu HV, RollandM, Hammer SM, Sobieszczyk ME. Translational research insights from completed HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S150-4.
27. Fideli US, Allen SA, Musonda R, et al. Virologic and immunologic determinants of heterosexual transmission of HIV-type 1 (HIV-1) in Africa. AIDS Res Hum Retrovir. 2001;17:901-10. (Pubitemid 32881333)
28. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-9. (Pubitemid 30177052)
29. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365: 493-505.
30. Shelton JD. HIV/AIDS. ARVs as HIV prevention: a tough road to wide impact. Science. 2011;334:1645-6.
31. Wilson DP. HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med. 2012;9:e1001231.
32. Modelling HIV. Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: models, data, and questions-towards evidence-based decision-making. PLoS Med. 2012;9:e1001259.
33. Granich R, Gupta S, Suthar AB, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9:446-69.
34. Iwuji CC, Orne-Gliemann J, Tanser F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials. 2013;14:230.
35. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIVacquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966-71.
36. Jain V, Byonanebye DM, Liegler T, et al. Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access. J Acquir Immune Defic Syndr. 2014;65:327-32.
37. Chamie G, Kwarisiima D, Clark TD, et al. Uptake of communitybased HIV testing during a multi-disease health campaign in rural Uganda. PLoS One. 2014;9:e84317.
38. Vermund SH, Fidler SJ, Ayles H, Beyers N, Hayes RJ. Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. J Acquir Immune Defic Syndr. 2013;63(2):S221-7.
39. Cori A, Ayles H, Beyers N, et al. HPTN 071 (PopART): a clusterrandomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9:e84511.
40. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a clusterrandomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials. 2014;15:57.
41. Gray RH, Kigozi G, Serwadda D, et al.Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657-66.
42. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-56. (Pubitemid 46281312)
43. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.
44. Qian HZ, Ruan Y, Liu Y, et al. Lower odds of HIV among circumcised MSM in China and interaction with anal sexual role. Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA. 2014; p. 83. [Abstract 963].
45. Gray RH, Wawer MJ, Kigozi G. Programme science research on medical male circumcision scale-up in sub-Saharan Africa. Sex Transm Infect. 2013;89:345-9.
46. Mehta SD, Moses S, Agot K, et al. The long term efficacy of medical male circumcision against HIV acquisition. AIDS. 2013;27:2899-909.
47. Stringer JS, Stinson K, Tih PM, et al.Measuring coverage in MNCH: population HIV-free survival among children under two years of age in four African countries. PLoS Med. 2013;10:e1001424.
48. Stringer EM, Ekouevi DK, Coetzee D, et al. Coverage of nevirapine-based services to preventmother-to-child HIV transmission in 4 African countries. JAMA. 2010;304:293-302.
49. Ciampa PJ, Tique JA, Jumá N, et al. Addressing poor retention of infants exposed to HIV: a quality improvement study in rural Mozambique. J Acquir Immune Defic Syndr. 2012;60:e46-52.
50. Geelhoed D, Lafort Y, Chissale É, Candrinho B, Degomme O. Integrated maternal and child health services in Mozambique: structural health system limitations overshadow its effect on follow-up of HIV-exposed infants. BMC Health Serv Res. 2013;13:207.
51. Smith LR, Fisher JD, Cunningham CO, Amico KR. Understanding the behavioral determinants of retention in HIV care: a qualitative evaluation of a situated information, motivation, behavioral skills model of care initiation andmaintenance. AIDS Patient Care STDS. 2012;26:344-55.
52. Laisaar KT, Uusküla A, Sharma A, DeHovitz JA, Amico KR. Developing an adherence support intervention for patients on antiretroviral therapy in the context of the recent IDU-driven HIV/AIDS epidemic in Estonia. AIDS Care. 2013;25:863-73.
53. Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet. 2012;380: 367-77.
54. Park LS, Siraprapasiri T, PeerapatanapokinW,Manne J,Niccolai L, Kunanusont C. HIV transmission rates in Thailand: evidence of HIV prevention and transmission decline. J Acquir Immune Defic Syndr. 2010;54:430-6.
55. Hallett TB, Aberle-Grasse J, Bello G, et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm Infect. 2006;82 Suppl 1:i1-8.
56. Petersen Z, Myers B, van Hout MC, Plüddemann A, Parry C. Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries. Harm Reduct J. 2013;10:13.
57. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014-28.
58. Gowing LR, HickmanM, Degenhardt L.Mitigating the risk of HIV infection with opioid substitution treatment. Bull World Health Organ. 2013;91:148-9.
59. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.
60. Naar-King S, Parsons JT, Johnson AM. Motivational interviewing targeting risk reduction for people with HIV: a systematic review. Curr HIV AIDS Rep. 2012;9:335-43.
61. Lorimer K, Kidd L, Lawrence M, McPherson K, Cayless S, Cornish F. Systematic review of reviews of behavioural HIV prevention interventions among men who have sex with men. AIDS Care. 2013;25:133-50.
62. Gurman TA, Rubin SE, Roess AA. Effectiveness of mHealth behavior change communication interventions in developing countries: a systematic review of the literature. J Health Commun. 2012;17 Suppl 1:82-104.
63. Parkhurst JO. HIV prevention, structural change and social values: the need for an explicit normative approach. J Int AIDS Soc. 2012;15(1):1-10.
64. Vermund SH, Tique JA, Cassell HM, Pask ME, Ciampa PJ, Audet CM. Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr. 2013;63 Suppl 1: S12-25.
65. Vermund SH, Hayes RJ. Combination prevention: new hope for stopping the epidemic. Curr HIV AIDS Rep. 2013;10:169-86.
66. Chang LW, Serwadda D, Quinn TC, Wawer MJ, Gray RH, Reynolds SJ. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis. 2013;13:65-76.
67. Hayes R, Sabapathy K, Fidler S. Universal testing and treatment as an HIV prevention strategy: research questions and methods. Curr HIV Res. 2011;9:429-45.
68. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV AIDS Rep. 2011;8:62-72.
69. Smith K, Powers KA,Kashuba AD, CohenMS. HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS. 2011;6:315-25.
70. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis. 2010;51:725-31.
71. Bowser D, Sparkes SP,Mitchell A, et al. Global Fund investments in human resources for health: innovation and missed opportunities for health systems strengthening. Health Policy Plan. 2013. [Epub ahead of print]. doi:10.1093/heapol/czt080. PubMed PMID: 24197405.
72. Goosby E, Dybul M, Fauci AS, et al. The United States President's Emergency Plan for AIDS Relief: a story of partnerships and smart investments to turn the tide of the global AIDS pandemic. J Acquir Immune Defic Syndr. 2012;60 Suppl 3:S51-6.
73. El-Sadr WM, Holmes CB, Mugyenyi P, et al. Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr. 2012;60 Suppl 3:S96-104.
74. April MD, Wood R, Berkowitz BK, et al. The survival benefits of antiretroviral therapy in South Africa. J Infect Dis. 2014;209:491-9.
75. Vermund SH.Massive benefits of antiretroviral therapy in Africa. J Infect Dis. 2014;209:483-5.
76. Vermund SH, Sidat M, Weil LF, Tique JA, Moon TD, Ciampa PJ. Transitioning HIV care and treatment programs in southern Africa to full local management. AIDS. 2012;26:1303-10.
77. Hull MW,Wu Z, Montaner JS. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS. 2012;7:579-86.
78. Schouten EJ, Jahn A, Ben-SmithA, et al. Antiretroviral drug supply challenges in the era of scaling up ART in Malawi. J Int AIDS Soc. 2011;(Suppl 1):S4.
79. Boyer S, Clerc I, Bonono CR, Marcellin F, Bilé PC, Ventelou B. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: individual and healthcare supply-related factors. Soc Sci Med. 2011;72:1383-92.
80. Pasquet A, Messou E, Gabillard D, et al. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One. 2010;5:e13414.
81. Muhamadi L, Nsabagasani X, Tumwesigye MN, et al. Inadequate pre-antiretroviral care, stock-out of antiretroviral drugs and stigma: policy challenges/bottlenecks to the new WHO recommendations for earlier initiation of antiretroviral therapy (CD <350 cells/ microL) in eastern Uganda. Health Policy. 2010;97:187-94.
82. Tankwanchi ABS, Özden C, Vermund SH. Physician emigration from sub-Saharan Africa to the United States: analysis of the 2011 AMA Physician Masterfile. PLoS Med. 2013;10:e1001513.
83. Pettifor A, Bekker LG, Hosek S, et al. Preventing HIV among young people: research priorities for the future. J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S155-60.
84. Vermund SH, Narayan KMV, Glass RI. Non-communicable diseases in HIV Survivors. Sci Transl Med. 2014; [In press]
85. Oluwole D, Kraemer J. Pink Ribbon Red Ribbon. Innovative publicprivate partnership: a diagonal approach to combating women's cancers in Africa. Bull World Health Organ. 2013;91:691-6.
86. Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH. Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential. Cancer Prev Res. 2012;5:11-7.
87. • Dionne KY, Gerland P, Watkins S. AIDS exceptionalism: another constituency heard from. AIDS Behav. 2013;17:825-31. The authors' qualitative research suggests Malawians value many other issues ahead of HIV care.
88. Emanuel EJ. PEPFAR and maximizing the effects of global health assistance. JAMA. 2012;307:2097-100.
89. Leach-Kemon K, Chou DP, Schneider MT, Tardif A, Dieleman JL, Brooks BP, et al. The global financial crisis has led to a slowdown in growth of funding to improve health in many developing countries. Health Aff. 2012;31:228-35.
90. Schneider K, Garrett L. The end of the era of generosity? Global health amid economic crisis. Philos Ethics Humanit Med. 2009;4:1.
91. Holmes CB, Blandford JM, Sangrujee N, et al. PEPFAR's past and future efforts to cut costs, improve efficiency, and increase the impact of global HIV programs. Health Aff. 2012;31:1553-60.
92. Grépin KA. HIV donor funding has both boosted and curbed the delivery of different non-HIV health services in sub-Saharan Africa. Health Aff. 2012;31:1406-14.